Open AccessFolic Acid Modified Glucosamine/Methotrexate Polymer Targeted Therapy for Rheumatoid Arthritis
Author(s) -
Zongfang Zhang,
Jie Pang,
Yanxia Li,
Wenwen Yang,
Xinzhuang Cui,
Huaheng Xu
Publication year - 2022
Publication title -
journal of nanomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 66
eISSN - 1687-4129
pISSN - 1687-4110
DOI - 10.1155/2022/2443302
Subject(s) - methotrexate , rheumatoid arthritis , glucosamine , in vivo , pharmacology , cytotoxicity , folic acid , in vitro , combination therapy , materials science , medicine , chemistry , biochemistry , biology , microbiology and biotechnology
Objective. To develop a targeted drug for the treatment of rheumatoid arthritis. Methods. In this study, methotrexate (MTX) was combined with glucosamine (Glu) and modified with folic acid (FA) to prepare folic acid-glucosamine/methotrexate polymer (FA-Glu/MTX). The stability, sustained release, cytotoxicity, and therapeutic effect were evaluated based on in vitro and in vivo experiments. Results. FA-Glu/MTX had good stability, sustained release, and low cytotoxicity. In addition, the results of in vivo experiments proved that compared with MTX, FA-Glu/MTX has a stronger therapeutic effect on RA and has certain targeting properties. Conclusion. FA-Glu/MTX is expected to become a new option for RA treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom